â– LECTURE OVERVIEW: Delirium Tremens (DTs) is the most severe and life-threatening manifestation of the alcohol withdrawal syndrome.
â– HYPEREXCITABLE NEURAL MECHANISMS:
1. Chronic GABA Drive: Chronic alcohol use continuously stimulates inhibitory GABA-A receptors, prompting down-regulation of these receptors, and continually blocks excitatory NMDA glutamate receptors, prompting up-regulation of NMDA receptors.
2. Abrupt Cessation: When alcohol is abruptly discontinued, the sudden loss of inhibitory GABA stimulation paired with an unregulated glutamatergic drive causes severe, systemic central nervous system hyperexcitability.
3. Autonomic Storm: Drives a severe sympathetic storm, characterized by extreme hypertension, hyperthermia, tachycardic arrhythmias, and psychomotor agitation.
â– PHARMACOKINETIC & PHARMACODYNAMIC ATTRIBUTES:
Absorption and steady-state kinetics display high variability based on plasma protein binding levels, tissue volume of distribution (Vd), and hepatic CYP450 microsomal enzymatic clearance indices.
â– GENOMIC VARIANT CHARACTERISTICS:
Molecular profiling indicates that specific genetic subtypes exhibit varying levels of enzyme activity and drug-clearance efficiency.
[HY-BOARD-1112]
🌟 Dynamic Clinical Key:
DTs typically begins 48-96 hours after the last drink, presenting with altered sensorium, disorientation, and vivid visual/tactile hallucinations (e.g., crawling insects). First-line treatment is aggressive intravenous Benzodiazepines (e.g., Diazepam, Lorazepam) to restore GABAergic inhibition and prevent status epilepticus. Closely monitor serum plasma concentrations if drugs display a narrow therapeutic window to mitigate toxic peaks. Genetic screening profiles can help tailor precise therapeutic doses for optimal patient outcomes.